A New Ketamine-Based Candidate Continues to Impress in Early Trials
A promising new entrant in the ketamine-based treatment space is drawing attention from psychiatrists and patients alike. BPL-003, an intranasal ketamine formulation developed by Bioxcel Therapeutics, has released Phase 2a Part 2 trial results showing continued and sustained reductions in depressive symptoms among patients with treatment-resistant depression (TRD). The findings were highlighted in Psychiatric Times in April 2026.
Treatment-resistant depression — typically defined as depression that has not responded to at least two adequate antidepressant trials — affects an estimated 30% of people diagnosed with major depressive disorder. For this population, options remain limited and the search for reliable, lasting relief is urgent. BPL-003's Phase 2a findings add to a growing body of evidence suggesting that ketamine delivered via nasal spray may offer a meaningful path forward.
What the Phase 2a Results Actually Tell Us
Phase 2a trials are early-stage studies primarily designed to assess safety, tolerability, and preliminary efficacy in a small patient population. They are not large randomized controlled trials, and results — however encouraging — should be interpreted with appropriate caution. That said, Part 2 of this trial is notable because it extends the observation window, offering data on whether initial symptom improvements hold over time rather than fading after the acute treatment phase.
Sustained symptom reduction is particularly meaningful in the TRD context. One of the longstanding criticisms of ketamine therapy, including the FDA-approved esketamine nasal spray Spravato, is that effects can be short-lived and require ongoing maintenance dosing. If BPL-003 can demonstrate durable response in later-phase trials, it could represent a clinically significant advancement over existing options.
It is worth noting that BPL-003 uses racemic ketamine — the same form used in most IV infusion clinics — rather than esketamine (the S-enantiomer used in Spravato). The nasal delivery mechanism, however, differentiates it from the IV route that dominates current off-label clinical practice. Intranasal delivery offers potential advantages in terms of ease of administration and the possibility of supervised at-home or clinic-based use without the need for IV access.
Key Takeaway for Patients
BPL-003 is still in early-stage clinical trials and is not available to patients outside of research settings. These results are encouraging, but Phase 2a data is preliminary. Larger, placebo-controlled Phase 3 trials are needed before any regulatory approval could be considered. Patients seeking ketamine therapy today should discuss currently available options — including IV ketamine infusions and FDA-approved esketamine (Spravato) — with a qualified provider.
What This Means for the Broader Ketamine Therapy Landscape
For patients and families navigating the ketamine therapy space, BPL-003's progress is worth monitoring for several reasons.
Expanding the delivery menu. Right now, patients considering ketamine have two primary clinical routes: off-label IV infusions administered at specialized clinics, or esketamine (Spravato) nasal spray, which is FDA-approved for TRD and major depressive disorder with acute suicidal ideation. A third intranasal racemic ketamine option, if approved, could increase competition in the market and potentially improve access and affordability over time.
The durability question. The emphasis on sustained symptom reduction in BPL-003's trial reporting signals that developers are paying close attention to one of the field's biggest challenges — keeping patients well between doses. Patients researching ketamine therapy should ask any prospective provider not just about initial response rates, but about maintenance protocols and long-term outcome data.
Regulatory pathway considerations. Spravato's FDA approval required a Risk Evaluation and Mitigation Strategy (REMS) program due to concerns about dissociation and sedation. Any future nasal ketamine product would likely face similar scrutiny. This means that even if BPL-003 advances successfully through trials, it would almost certainly require in-clinic administration under medical supervision rather than fully unsupervised home use.
What this does not change — yet. For patients seeking treatment today, BPL-003 is not an option. Phase 3 trials, FDA review, and approval processes typically span several years. Current patients should make decisions based on what is available now, not on pipeline candidates, however promising.
Questions to Ask Your Provider
If you are evaluating ketamine therapy for treatment-resistant depression, the BPL-003 news is a useful reminder to approach the space with informed curiosity. Some questions worth raising with any prospective ketamine provider include: What evidence base supports the protocol you use? How do you define and measure treatment response? What does a maintenance plan look like if I respond initially? How does your clinic stay current with emerging research? A provider who engages seriously with these questions is a better sign than one who simply markets outcomes without explaining the evidence behind them.
The ketamine therapy field is evolving quickly. Staying informed — without getting ahead of the evidence — is the most practical stance patients and families can take right now.
Share